Annals of Internal MedicineCardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes (T2D) w. Sodium–Glucose Cotransporter-2 Inhibitors (SGLT-2i) vs. Metformin

A new study published in Annals of Internal Medicine looks at the link between cardiovascular disease among adults with type 2 diabetes, which might be more prevalent than previously thought. This study compares cardiovascular outcomes in patients taking first line metformin vs. SGLT-2 inhibitors, based on claims data over a 7-year period. SGLT-2 inhibitor use was associated with lower rates of hospitalization for heart failure and all cause mortality. Rates for MI and stroke were similar for the two treatments.